Bolder BioTechnology, Inc. Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
8/30/2012 12:01:34 PM
More...
|
Bolder BioTechnology, Inc. Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
11/4/2010 6:53:13 AM
More...
|
Bolder BioTechnology, Inc. Announces $600,000 Grant from National Institutes of Health (NIH) to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
8/18/2010 11:34:54 AM
More...
|
Bolder BioTechnology, Inc. Receives $1.2 Million National Institutes of Health (NIH) Grant to Continue Development of Long-Acting EPO Analog for Chronic Kidney Disease
9/17/2009 11:24:53 AM
More...
|
Bolder BioTechnology, Inc. Receives $1.9 Million National Institutes of Health (NIH) Grant to Continue Development of Long-Acting Growth Hormone Product
12/17/2008 7:47:41 AM
More...
|
Bolder BioTechnology, Inc. Receives $1.6 million National Institutes of Health (NIH) Grant to Continue Development of Multiple Sclerosis Drug
10/15/2008 11:28:41 AM
More...
|
Bolder BioTechnology, Inc. Awarded National Institutes of Health (NIH) Phase I SBIR Grant To Develop Bioscavenger Protein For Detoxifying Nerve Agents
10/19/2005 5:13:19 PM
More...
|
Bolder BioTechnology, Inc. Receives U.S. Patent For Process Used To Manufacture Proprietary Second-Generation Protein Pharmaceuticals
10/19/2005 5:12:36 PM
More...
|
Bolder BioTechnology, Inc. Awarded National Institutes of Health (NIH) Grant To Develop Novel Arthritis Treatment
10/19/2005 5:12:31 PM
More...
|
Bolder BioTechnology, Inc. Receives National Institutes of Health (NIH) Grant For Preclinical Development Of Proprietary Erythropoiesis-Stimulating Protein
10/19/2005 5:12:16 PM
More...
|
|